UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
______________________
Date of Report (Date of earliest event reported): November 13, 2017

OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-38242 | 26-1761833
(Commission File Number) | (I.R.S. Employer Identification Number)

2850 Frontier Drive Warsaw, Indiana | 46582
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [X]

Item 7.01. Regulation FD Disclosure.
OrthoPediatrics Corp. (the “Company”) will be presenting at the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017, in New York City. Mark Throdahl, President and Chief Executive Officer, and Fred Hite, Chief Financial Officer will be presenting on the Company at 10:15 (Eastern). An audio webcast of the presentation will be available at the Company’s investor relations website, http://ir.orthopediatrics.com. A replay of the presentation will also be available for 90 days. The officers also intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of the presentation.
The Company does not intend for this Item 7.01 or Exhibit 99.1 to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.

(d) | Exhibits |
| Exhibit No. | Description
| 99.1 | OrthoPediatrics Corp. Investor Presentation dated November 2017. This exhibit shall not be deemed "filed" for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

* * * * * *
17526818.1

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| OrthoPediatrics Corp.
Date: November 13, 2017 | By: | /s/ Daniel J. Gerritzen
|  | Daniel J. Gerritzen, General Counsel and Secretary